Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines

(2014) Tomáš Hanke   EXPERT OPINION ON BIOLOGICAL THERAPY

Translating HIV Sequences into Quantitative Fitness Landscapes Predicts Viral Vulnerabilities for Rational Immunogen Design

(2013) Andrew L. Ferguson et al.   IMMUNITY

Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1

(2013) Nicola Borthwick et al.   MOLECULAR THERAPY

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

(2013) Caroline Ogwang et al.   PLoS One

Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers

(2013) Sanjay Mehendale et al.   PLoS One

Use of Adenovirus Serotype 5 Vaccine Vectors in Seropositive, Uncircumcised Men: Safety Lessons from the Step Trial

(2012) T. L. Richie et al.   JOURNAL OF INFECTIOUS DISEASES

Reply to Richie and Villasante

(2012) A. Duerr et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine

(2012) Maria L. Knudsen et al.   JOURNAL OF VIROLOGY

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

(2012) Susanne H Sheehy et al.   MOLECULAR THERAPY

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults

(2012) Michael C. Keefer et al.   PLoS One

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

(2012) S. Colloca et al.   Science Translational Medicine

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques

(2011) Maximillian Rosario et al.   AIDS

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

(2011) Nicole Frahm et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques

(2010) Maximillian Rosario et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate

(2010) Jeffrey R. Currier et al.   PLoS One

Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive

(2010) Natalie A. Hutnick et al.   VACCINE

A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers

(2009) Vadakkuppatu Devasenapathi Ramanathan et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy

(2009) M. Dudareva et al.   VACCINE

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

(2008) Sheena McCormack et al.   VACCINE

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

(2008) Walter Jaoko et al.   VACCINE